a polysaccharide called hyaluronan

New polysaccharide may help combat multidrug resistance in cancer

Bethesda, MD – In a recent study published in the Journal of Biological Chemistry, scientists report that a molecule previously thought to play a purely structural and inert role in cells is actually involved in multidrug resistance in cancer. Using antagonists for this molecule, the researchers were able to sensitize drug resistant breast cancer cells to chemotherapeutic drug treatment.
The research appears as the "Paper of the Week" in the May 27 issue of the Journal of Biological Chemistry, an American Society for Biochemistry and Molecular Biology journal.

Multidrug resistance is very common in most types of cancers, making it one of the leading problems in cancer therapy. It is often caused by an increase in the cell's production of proteins that transport drugs out of the cell, preventing the drugs from combating cancer.

Previously, Dr. Bryan P. Toole and his coworkers, Drs. Suniti Misra and Shibnath Ghatak, of the Medical University of South Carolina noticed that small pieces, or oligomers, of a polysaccharide called hyaluronan were able to sensitize drug-resistant breast cancer cells to several different chemotherapeutic drugs. He believed that the polysaccharide oligomers were binding to a receptor for hyaluronan (called CD44) and preventing it from initiating a signaling cascade that would result in drug resistance.

"It is very surprising that hyaluronan is involved in drug resistance," admits Dr. Toole. "Most scientists think of hyaluronan as a structural and inert molecule. In adult tissues it plays two roles. First, it assists in tissue hydration and in biophysical properties such as resilience. Second, it forms a template to which matrix proteins attach and form important extracellular structural complexes."

Hyaluronan also accumulates around the outside of cells during disease processes such as early atherogenesis, persistent inflammation, and cancer. In recent years, however, hyaluronan has also been shown to induce signaling pathways in inflammatory, embryonic and cancer cells.

In their current Journal of Biological Chemistry paper, Dr. Toole and his colleagues report on further studies which indicate that hyaluronan increases the cellular production of a multidrug transporter protein by binding to CD44. They discovered that antagonist molecules that bind to hyaluronan and prevent it from interacting with CD44 were able to sensitize multidrug resistant breast cancer cells to chemotherapeutic drugs. The researchers also found that increasing hyaluronan synthesis in cells increased resistance to drug treatment.

"Our work indicates that hyaluronan antagonists, for example small hyaluronan oligomers, reverse the malignant properties of cancer cells, including proliferation, invasiveness, and drug resistance," explains Dr. Toole. "Hyaluronan oligomers are non-toxic, non-immunogenic, and readily applicable to several proliferative disease processes, especially cancer. We are hoping that hyaluronan antagonists can be used in conjunction with chemotherapy such that much lower and less toxic doses of chemotherapeutic agents can be used."

###

The Journal of Biological Chemistry's Papers of the Week is an online feature which highlights the top one percent of papers received by the journal. Brief summaries of the papers and explanations of why they were selected for this honor can be accessed directly from the home page of the Journal of Biological Chemistry online at www.jbc.org.

The American Society for Biochemistry and Molecular Biology (ASBMB) is a nonprofit scientific and educational organization with over 11,000 members in the United States and internationally. Most members teach and conduct research at colleges and universities. Others conduct research in various government laboratories, nonprofit research institutions, and industry.

Founded in 1906, the Society is based in Bethesda, Maryland, on the campus of the Federation of American Societies for Experimental Biology. The Society's primary purpose is to advance the sciences of biochemistry and molecular biology through its publications, the Journal of Biological Chemistry, The Journal of Lipid Research, Molecular and Cellular Proteomics, and Biochemistry and Molecular Biology Education, and the holding of scientific meetings.

For more information about ASBMB, see the Society's website at asbmb.org.

Contact: Nicole Kresge nkresge@asbmb.org 301-634-7415 American Society for Biochemistry and Molecular Biology